WuXi Biologics (Cayman) Inc 02269
News
WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
WuXi AppTec Shares Rally Amid Sectorwide Gains After Tech Selloff, China Policy Support
WuXi Biologics Plans to Buy Back Up to US$400 Million of Shares
Chinese Pharma Stocks Fall on Potential U.S. Restrictions on Drugs

